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Background
Therapy of advanced melanoma has been improved with
the advent of BRAF inhibitors. However, a limitation to
such treatment is the occurrence of resistance. Several
mechanisms have been implied in the development of
resistance, which in most cases lead to downstream
MEK reactivation. In order to overcome resistance MEK
inhibitors are being clinically developed with promising
results. However, also in this case resistance inevitably
occurs. It is commonly believed that the establishment
of resistance is facilitated by adaptive changes that take
place in cancer cells shortly after exposure to kinase
inhibitors. Our laboratory is interested in the identifica-
tion of these early adaptive changes with the intent to
discover additional targets for therapeutic intervention.
Methods
Four melanoma cell lines were tested: LOX IMVI and
M14 (BRAF V600E), MST-L (BRAF V600R) and WM266
(BRAF V600D). RTK arrays (R&D) were carried out with
protein extracts from untreated of BRAFi and MEKi trea-
ted cells. Western blot analysis was performed on total
protein extracts using anti-ErbB3, anti-AKT and anti-ERK
1/2 antibodies. The growth inhibitory effects of multiple
combinations of BRAF and MEK inhibitors and/or anti-
ErbB3 mAbs were evaluated by colony formation assays.
Mouse xenograft studies were carried out with M14 cells
injected s.c. at the dose of 5x 106 cells. Drug treatments
began when tumors reached a mean volume of 100 mm3
and tumor growth was measured by caliper.
Results
We show that ErbB3 is the main RTK rapidly hyperpho-
sphorylated in response to BRAF or MEK inhibition in
melanoma cell lines harboring a variety of V600 BRAF
mutations. This results in a strong activation of phospho-
AKT. ErbB3 activation, which is caused by increased auto-
crine production of neuregulin, can be fully abrogated by
two distinct anti-ErbB3 monoclonal antibodies, A3 and
A4. Most importantly these two mAbs individually or in
combination strongly enhance the ability of different
BRAF/MEK inhibitors to silence the oncogenic MAPK
and AKT pathways. This results in potentiation of growth
inhibition and of apoptosis. Preliminary xenograft studies
confirm that administration of BRAF inhibitors together
with anti-ErbB3 mAbs exerts a more profound inhibition
of tumor growth than single treatments which is accompa-
nied by a stronger downregulation of oncogenic signaling.
Conclusions
Feedback activation of ErbB3/AKT phosphorylation is a
fast and common response of melanoma cells to BRAF
and/or MEK inhibitors. Our results suggest that combina-
torial treatment of melanoma patients with BRAF/MEK
inhibitors together anti-ErbB3 antibodies should be further
explored as a potentially helpful clinical approach.
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